Compare Amylx Pharmaceuticals Inc (AMLX) vs US Global Jets ETF (JETS) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

JETS trades at $32.54, down 0.31% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights mixed sentiment, including JetBlue's earnings beat lifting airline stocks but fuel cost pressures and geopolitical risks weighing on the sector. The ETF faces volatility from oil price swings and competitive ETF comparisons.

Outlook is cautious due to high sensitivity to fuel costs and travel demand cycles. Opportunities exist if oil remains low, but risks from Middle East tensions and economic slowdowns could pressure earnings. Investors should weigh JETS' cyclical nature against broader aerospace ETFs for diversification.